| Category | Min Lots | Shares | Amount |
|---|---|---|---|
| Retail (sNII) | 1 | 33 | ₹14,784 |
| HNI / NII | 14 | 462 | ₹2,06,976 |
| bHNI / bNII | 68 | 2,244 | ₹10,05,312 |
| Category | Sub (×) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 63,61,606 (50.00%) | — | ₹28,500.00 Cr |
| NII / HNI (Total) | — | 19,08,483 (15.00%) | — | ₹8,550.00 Cr |
| Retail Investors | — | 44,53,125 (35.00%) | — | ₹19,950.00 Cr |
| Total ** | — | 1,27,23,214 (100.00%) | — | ₹569,999.99 Cr |
| Metric | 30 Jun 2023 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Revenue | 234.37 | 935.58 | 803.41 |
| PAT | 17.59 | 67.95 | 63.95 |
| EBITDA | — | — | — |
| Net Worth | 294.27 | 276.46 | 208.56 |
| Total Assets | 1086.16 | 704.41 | 575.48 |
| Reserves | 317.51 | 228.51 | 196.61 |
| Borrowings | 441.90 | 235.19 | 198.18 |
Incorporated in January 2005, Innova Captab Limited is a pharmaceutical company operating in three business segments. Firstly, it provides contract development and manufacturing services to Indian pharmaceutical companies. Secondly, the company has a domestic business dealing in branded generics. And thirdly, the company has an international business that deals in branded generics.
The company's product portfolio includes tablets, capsules, dry syrups, dry powder injections, ointments and liquid medicines.
In the financial year 2023 and the three months ended June 30, 2023, the company produced and sold more than 600 different types of generics. These products were distributed under the company's own brands in the Indian market through a network of approximately 5,000 distributors and stockists and over 150,000 retail pharmacies. In addition, Innova Capitab exported its branded generic products to 20 and 16 countries in FY2023 and the three months ended June 30, 2023, respectively.
As of October 31, 2023, the company employed a team of 29 scientists and engineers in its research and development laboratory. The company's manufacturing facility is located in Buddi, Haryana
The company's customer base includes Cipla, Glenmark Pharmaceuticals, Wockhardt, Corona Remedies, Emcure Pharmaceuticals, Lupin, Medley Pharmaceuticals, Eris Healthcare, Zuventus Healthcare, Ajanta Pharma, Mankind Pharma, and others.
As of October 31, 2023, the company has 200 active product registrations and 20 registrations pending renewal with international authorities. In addition, 218 new registration applications are being processed with international authorities.